The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma
Abstract
To date, genomic analyses of hepatocellular carcinoma (HCC) have been limited to early stages obtained from liver resection. We aim to describe the genomic profiling of HCC from early to advanced stages. We analyzed 801 HCC from 720 patients (410 resections, 137 transplantations, 122 percutaneous ablations, and 52 noncurative) for 190 gene expressions and for 31 gene mutations. Forty‐one advanced HCC and 156 whole exome of Barcelona Clinic Liver Cancer (BCLC) 0/A were analyzed by whole‐exome sequencing. Genomic profiling was correlated with tumor stages, clinical features, and survival. Our cohort included patients classified in BCLC stage 0 (9.4%), A (59.5%), B (16.2%), and C (14.9%). Among the overall 801 HCC, the most frequently mutated genes were telomerase reverse transcriptase (TERT) (58.1%), catenin beta 1 (CTNNB1) (30.7%), tumor protein 53 (TP53; 18.7%), AT‐rich interaction domain 1A (ARID1A) (13%), albumin (11.4%), apolipoprotein B (APOB) (9.4%), and AXIN1 (9.2%). Advanced‐stage HCC (BCLC B/C) showed higher frequencies of splicing factor 3b subunit 1 (SF3B1) (P = 0.0003), TP53 (P = 0.0006), and RB Transcriptional Corepressor 1 mutations (P = 0.03). G1‐G6 transcriptomic classification and the molecular prognostic 5‐gene score showed different distributions according to the stage of the disease and the type of treatment with an enrichment of G3 (P < 0.0001), poor prognostic score (P < 0.0001), and increased proliferation and dedifferentiation at the transcriptomic level in advanced HCC. The 5‐gene score predicted survival in patients treated by resection (P < 0.0001) and ablation (P = 0.01) and in advanced HCC (P = 0.04). Twenty‐two percent of advanced HCC harbored potentially druggable genetic alterations, and MET amplification was associated with complete tumor response in patients with advanced HCC treated by a specific MET inhibitor. Conclusion: Genomic analysis across the different stages of HCC revealed the mechanisms of tumor progression and helped to identify biomarkers of response to targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationComprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Self-citationTrans-ancestry mutational landscape of hepatocellular carcinoma genomes
Totoki, Y., Tatsuno, K., Covington, K. R., Ueda, H., Creighton, C. J., Kato, M., Tsuji, S., Donehower, L. A., Slagle, B. L., Nakamura, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.3126 · Cited by 781 · cited 3×
“166 control (tumor protein 53 [TP53], cyclin-dependent kinase inhibitor 2A [CDKN2A]), Wnt/b-catenin (catenin beta 1 [CTNNB1], AXIN1), epigenetic (AT-rich interaction domain 1A [ARID1A], AT-rich interaction domain 2 [ARID2], lysine methyltransferase 2D [MLL2]), and oxidative stress (nuclear factor, erythroid 2 like 2 […”
Background
Cited by
Advances in molecular classification and precision oncology in hepatocellular carcinoma
Rebouissou, S., & Nault, J.-C. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.017 · Cited by 575
Self-citationBiomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Piñero, F., Dirchwolf, M., & Pessôa, M. G. (2020) · Cells · doi:10.3390/cells9061370 · Cited by 498
Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis
Filliol, A., Saito, Y., Nair, A., Dapito, D. H., Yu, L.-X., Ravichandra, A., Bhattacharjee, S., Affo, S., Fujiwara, N., Su, H., et al. (2022) · Nature · doi:10.1038/s41586-022-05289-6 · Cited by 349
Self-citationMolecular therapies for HCC: Looking outside the box
Faivre, S., Rimassa, L., & Finn, R. S. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.010 · Cited by 326
Self-citationHepatocellular carcinoma: old friends and new tricks
Kim, E., & Viatour, P. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00527-1 · Cited by 307
Metadata
- Authors
- Nault, J., Martin, Y., Caruso, S., Hirsch, T. Z., Bayard, Q., Calderaro, J., Charpy, C., Copie‐Bergman, C., Ziol, M., Bioulac‐Sage, P., Couchy, G., Blanc, J., Nahon, P., Amaddeo, G., Ganne‐Carrie, N., Morcrette, G., Chiche, L., Duvoux, C., Faivre, S., Laurent, A., Imbeaud, S., Rebouissou, S., Llovet, J. M., Seror, O., Letouzé, E., & Zucman‐Rossi, J.
- Venue
- Hepatology
- Published
- 2019-08-12
- Volume
- 71
- Issue
- 1
- Pages
- 164-182
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2949377065
- Cited by
- 207
- References
- 4
- FWCI
- 15.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1002/hep.30811
- The paper
- Nault, J., Martin, Y., Caruso, S., Hirsch, T. Z., Bayard, Q., Calderaro, J., Charpy, C., Copie‐Bergman, C., Ziol, M., Bioulac‐Sage, P., Couchy, G., Blanc, J., Nahon, P., Amaddeo, G., Ganne‐Carrie, N., Morcrette, G., Chiche, L., Duvoux, C., Faivre, S., . . . Zucman‐Rossi, J. (2020). Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. Hepatology. https://doi.org/10.1002/hep.30811
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.